Skip to content
DealForma Logo White 250x42 1
  • Features
  • Pricing
  • Blog
    • DealForma Research
    • Media Coverage
  • Sign in
  • Features
  • Pricing
  • Blog
    • DealForma Research
    • Media Coverage
  • Sign in
  • Sign In
  • Schedule a demo

DealForma Research

Recent Articles

Biopharma Therapeutics and Platforms IPO, Follow-on, and PIPE Issuances – 2025 Review

Biopharma Therapeutics and Platforms IPO, Follow-on, and PIPE Issuances – 2025 Review

  • March 23, 2026
Biopharma Therapeutics and Platforms Venture Funding - 2025 Review

Biopharma Therapeutics and Platforms Venture Funding – 2025 Review

  • March 18, 2026
Biopharma Therapeutics and Platforms M&A - 2025 Review

Biopharma Therapeutics and Platforms M&A – 2025 Review

  • March 9, 2026
Biopharma Therapeutics and Platforms R&D Partnerships - 2025 Review

Biopharma Therapeutics and Platforms R&D Partnerships – 2025 Review

  • February 26, 2026
Dermatology M&A - 2024-2025 Review

Dermatology M&A – 2024-2025 Review

  • February 23, 2026
global healthcare and live sciences

Global Healthcare and Life Sciences IPO Activity – 2025 Review

  • February 13, 2026
Global Healthcare and Life Sciences Venture Funding – 2025 Review

Global Healthcare and Life Sciences Venture Funding – 2025 Review

  • February 6, 2026
Global Healthcare and Life Sciences M&A - 2025 Review

Global Healthcare and Life Sciences M&A – 2025 Review

  • February 2, 2026
Global Healthcare and Life Sciences R&D Partnerships - 2025 Review

Global Healthcare and Life Sciences R&D Partnerships – 2025 Review

  • January 26, 2026
Global Healthcare and Life Sciences – 2025 Review

Global Healthcare and Life Sciences – 2025 Review

  • January 21, 2026
AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs - 2025 Review

AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs – 2025 Review

  • January 13, 2026
Infectious R&D Partnerships, M&A and Venture Funding - Q3 2025 Review

Infectious R&D Partnerships, M&A and Venture Funding – Q3 2025 Review

  • January 13, 2026
Endocrine-Metabolic R&D Partnerships, M&A and Venture Funding - Q3 2025 Review

Endocrine-Metabolic R&D Partnerships, M&A and Venture Funding – Q3 2025 Review

  • January 3, 2026
Previous Page1 Page2 Page3 Page4 Page5 Next

All of this by stage, disease indication, modality, target…

Schedule your demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin X Social Media White Icon

Database

  • Features
  • Pricing
  • Features
  • Pricing

Company

  • About Us
  • Analysis / Blog
  • Case Studies
  • Contact Us
  • About Us
  • Analysis / Blog
  • Case Studies
  • Contact Us

Comparisons

  • Alternative to Evaluate Pharma
  • Alternative to BioSciDB
  • Alternative to Clarivate Cortellis
  • Alternative to BioCentury BCIQ
  • Alternative to PitchBook
  • Other Database Alternatives
  • Alternative to Evaluate Pharma
  • Alternative to BioSciDB
  • Alternative to Clarivate Cortellis
  • Alternative to BioCentury BCIQ
  • Alternative to PitchBook
  • Other Database Alternatives
  • Made in San Mateo, CA and around the world
  • support@dealforma.com
  • (650) 353-9363

Website Design by Once Interactive

  • Terms
  • Privacy
  • Copyright © 2026 DealForma
  • Features
  • Pricing
  • Blog
    • DealForma Research
    • Media Coverage
  • Sign in
Logo